Header Logo

Connection

Simiso Sokhela to Anti-HIV Agents

Back to Details
This is a "connection" page, showing publications Simiso Sokhela has written about Anti-HIV Agents.
Simiso Sokhela
Connection Strength
2,511
Anti-HIV Agents
  1. Roadmap for Achieving Universal Antiretroviral Treatment. Annu Rev Pharmacol Toxicol. 2023 01 20; 63:99-117.
    View in: PubMed
    Score: 0,444
  2. Long-acting antiretroviral therapy in low-income and middle-income countries: considerations for roll-out. Curr Opin HIV AIDS. 2025 Jan 01; 20(1):19-24.
    View in: PubMed
    Score: 0,126
  3. DORA: 48-week weight and metabolic changes in Black women with HIV, in a phase IIIb switch study from dolutegravir- or efavirenz- to doravirine-based first-line antiretroviral therapy. HIV Med. 2025 Jan; 26(1):81-96.
    View in: PubMed
    Score: 0,125
  4. Low CD4 counts predict excessive weight gains during first-line treatment for HIV. J Antimicrob Chemother. 2024 Sep 03; 79(9):2369-2378.
    View in: PubMed
    Score: 0,124
  5. Two-drug regimens for the treatment of HIV in Africa. Lancet HIV. 2024 Jun; 11(6):e419-e426.
    View in: PubMed
    Score: 0,121
  6. Pharmacogenetics of tenofovir renal toxicity in HIV-positive Southern Africans. Pharmacogenet Genomics. 2023 07 01; 33(5):91-100.
    View in: PubMed
    Score: 0,113
  7. Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG. Clin Infect Dis. 2023 04 17; 76(8):1492-1495.
    View in: PubMed
    Score: 0,113
  8. Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population. CPT Pharmacometrics Syst Pharmacol. 2023 06; 12(6):821-830.
    View in: PubMed
    Score: 0,113
  9. Pharmacogenetics of tenofovir clearance among Southern Africans living with HIV. Pharmacogenet Genomics. 2023 06 01; 33(4):79-87.
    View in: PubMed
    Score: 0,112
  10. Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries. AIDS. 2023 05 01; 37(6):1009-1011.
    View in: PubMed
    Score: 0,111
  11. Concentration-response relationships of dolutegravir and efavirenz with weight change after starting antiretroviral therapy. Br J Clin Pharmacol. 2022 03; 88(3):883-893.
    View in: PubMed
    Score: 0,104
  12. The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/efavirenz. AIDS. 2021 12 15; 35(Suppl 2):S117-S125.
    View in: PubMed
    Score: 0,103
  13. Cost and cost-effectiveness of dolutegravir-based antiretroviral regimens: an economic evaluation of a clinical trial. AIDS. 2021 12 15; 35(Suppl 2):S173-S182.
    View in: PubMed
    Score: 0,103
  14. CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz. Clin Infect Dis. 2021 12 06; 73(11):e3902-e3909.
    View in: PubMed
    Score: 0,103
  15. Participants on Dolutegravir Resuppress Human Immunodeficiency Virus RNA After Virologic Failure: Updated Data from the ADVANCE Trial. Clin Infect Dis. 2021 08 16; 73(4):e1008-e1010.
    View in: PubMed
    Score: 0,101
  16. Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes. AIDS. 2021 08 01; 35(10):1657-1665.
    View in: PubMed
    Score: 0,100
  17. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. Lancet HIV. 2020 10; 7(10):e666-e676.
    View in: PubMed
    Score: 0,095
  18. Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial. Lancet HIV. 2019 07; 6(7):e428-e437.
    View in: PubMed
    Score: 0,086
  19. Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Low-Dose Stavudine Over 96 Weeks: A Multicountry Randomized, Noninferiority Trial. J Acquir Immune Defic Syndr. 2019 02 01; 80(2):224-233.
    View in: PubMed
    Score: 0,084
  20. Clinical deterioration during antituberculosis treatment in Africa: incidence, causes and risk factors. BMC Infect Dis. 2010 Mar 30; 10:83.
    View in: PubMed
    Score: 0,046
  21. Blood pressure increases are associated with weight gain and not antiretroviral regimen or kidney function: a secondary analysis from the ADVANCE trial in South Africa. J Int AIDS Soc. 2024 Jul; 27(7):e26268.
    View in: PubMed
    Score: 0,031
  22. Determinants of early change in serum creatinine after initiation of dolutegravir-based antiretroviral therapy in South Africa. Br J Clin Pharmacol. 2024 May; 90(5):1247-1257.
    View in: PubMed
    Score: 0,030
  23. Genetic Associations with Weight Gain among South Africans who Initiated Dolutegravir-Containing and Tenofovir-Containing Regimens. J Acquir Immune Defic Syndr. 2021 07 01; 87(3):1002-1009.
    View in: PubMed
    Score: 0,025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.